Clinical Trial Compensation: How Much Should You Pay Someone to Participate?
How much should you pay someone to take part in a clinical trial? Pay too little and you may not recruit enough participants. Pay too much and you might be accused of coercing people into studies they would otherwise avoid. Finding the balance between fair compensation and undue influence is one of the most debated ethical questions in clinical research, and the Clarity Clinical Solutions video on clinical trial compensation lays out the arguments on both sides.
Getting the amount right matters for more than ethics. Compensation acknowledges the time, effort, and inconvenience that participants contribute: travel costs, time off work, childcare arrangements. Fair compensation can also improve diversity by enabling people from lower income backgrounds to take part. Poorly designed compensation, by contrast, either exploits participants by paying too little or coerces them by paying too much.
Three types of payment
The video draws a careful line between three kinds of payment.
Reimbursement covers out-of-pocket expenses: travel, parking, meals, lodging. This is not controversial. It simply ensures participants are not financially harmed by taking part.
Payment is compensation for time and effort, an hourly wage similar to what participants might earn in a job.
Incentive is extra payment designed to encourage enrollment. This is where ethical concerns arise, because high incentives can override a person's better judgment about risks.
The ethical framework for trial compensation rests on four principles from research ethics: respect for persons, meaning participants are compensated fairly and not exploited; beneficence, meaning compensation should not blind participants to danger; justice, meaning the benefits and burdens of research are distributed fairly across populations; and voluntariness, meaning consent must be free from undue influence, so participants can say no without losing something important. These principles are the same ones that anchor the U.S. Common Rule, which requires that consent be sought under circumstances that minimize the possibility of coercion or undue influence.
How compensation is structured
Types of compensation vary widely. Per-visit payments are the most common, typically ranging from $25 to $200 per visit depending on how invasive and how long the visit is. Flat payments give participants a lump sum at completion. Staged payments release portions at milestones to encourage retention. Some trials offer non-cash compensation: free medical care, medication after the trial ends, or gift cards. Each type carries different ethical implications for coercion and fairness.
Undue influence occurs when an excessive offer overwhelms a person's ability to make a reasoned decision about risks. This is especially concerning for economically vulnerable populations. If the payment represents a large portion of someone's income, they may accept risks they would otherwise refuse. The line between fair compensation and undue influence depends on the participant's circumstances, not just the absolute amount. What is reasonable compensation for a middle-class professional might be coercive for someone living in poverty.
What the regulations say
Regulatory guidance on compensation comes from the Common Rule, FDA regulations, and the ICH E6 good clinical practice guideline. The Common Rule requires that consent be sought under circumstances that minimize the possibility of coercion or undue influence (45 CFR 46.116). Guidance from the HHS Office for Human Research Protections and the FDA emphasizes that compensation should be proportional to the time and inconvenience involved, not to the riskiness of the study. Paying people for taking risks is considered ethically problematic because it could be seen as purchasing their consent to be harmed.
The international standard points the same direction. ICH E6, the good clinical practice guideline that governs trials worldwide, requires that participants be informed about compensation in the informed consent process and that payments be reasonable and not present undue influence. In practice, this means the payment structure should be spelled out in the consent form: the amount, the schedule, and what happens to payment if the participant withdraws early.
Fairness across populations
Fairness is a major concern. Historically, clinical trials have under-enrolled minority and low-income populations, and adequate compensation can help address that disparity. But there is a parallel concern that the same compensation may be unfairly coercive for some groups while being too little for others. Some argue for tiered compensation based on participant income, though that raises its own questions about fairness and discrimination. Standardizing compensation across sites while accounting for local economic conditions is a practical challenge that most sponsors wrestle with.
The debate between paid and unpaid participation reflects different views on what motivates research volunteers. Some argue that participation should be altruistic, and that paying people commodifies the body and undermines the gift relationship in research. Others counter that requiring altruism unfairly burdens those who cannot afford to volunteer their time. In practice, most trials offer some compensation, and the debate has shifted from whether to pay to how much and under what conditions. The emerging consensus is that payment should compensate for time and burden, not for risk-taking.
Best practices for ethical compensation
The video closes with three best practices.
First, base payment on time and burden, not on risk. Tying payment to risk level could be seen as buying consent to be harmed.
Second, describe compensation clearly in the consent form, including the amount, the schedule, and the conditions for partial payment if the participant withdraws early.
Third, use institutional review board (IRB) review to evaluate whether the proposed compensation creates undue influence for the specific population being recruited, considering local economic conditions and participant vulnerability. An IRB is the committee that reviews research to protect participants, and it reviews payment arrangements as part of its oversight role.
The bottom line
Fair compensation respects participants' time and contribution without being so large that it overrides their judgment about risks. The key principles are simple: pay for time and burden, not for risk; describe compensation clearly in the consent process; and evaluate fairness in context, because the same amount can be appropriate for one population and coercive for another. The goal is not to avoid paying participants. It is to compensate them fairly without undermining the voluntariness of their consent.
This article is based on the Clarity Clinical Solutions video "Clinical Trial Compensation — How much should you pay someone to participate in a clinical trial?" Watch it here: Clinical Trial Compensation — How much should you pay someone to participate in a clinical trial?
References
- Clarity Clinical Solutions — Clinical Trial Compensation — How much should you pay someone to participate in a clinical trial? (video). https://www.youtube.com/watch?v=TUz78MVoW5U
- U.S. Department of Health and Human Services — 45 CFR 46.116, the Common Rule requirements for informed consent, including minimizing coercion or undue influence. https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-46/section-46.116
- ICH — Efficacy Guidelines, including the E6 good clinical practice guideline that governs compensation disclosure in consent processes worldwide. https://www.ich.org/page/efficacy-guidelines
- ClinicalTrials.gov — Learn About Studies, including what participants should know about costs and payment before joining a trial. https://clinicaltrials.gov/learn-about-studies